Dengue Vaccine in Pakistan: Is One Available Right Now?
In Pakistan, no dengue vaccine is confirmed for routine use, and the approved one, Dengvaxia, is being discontinued by its maker. Dengue vaccines do exist, so the useful questions are which product it is, whether it is registered in Pakistan, and who it is for.
Quick facts, checked 9 October 2026
- Pakistan, Dengvaxia: Pakistan’s drug regulator approved it, but not for routine mass immunisation, according to a September 2025 editorial. Singapore’s Ministry of Health says its maker has decided to discontinue it because of low global demand.
- Pakistan, Qdenga: not approved for use in Pakistan, according to the same editorial.
- Qdenga, EU label: two injections three months apart, from age 4. The EU summary says it must not be used in women who are pregnant or breastfeeding.
- What a vaccine does: prevents dengue in people who qualify. It does not treat a fever that has already started.
- India: this check did not confirm an official approval. Treat any news report with care, and confirm with CDSCO or a clinic.
Prefer to listen? This post as a 2 min video · Watch the video
Is a dengue vaccine available in Pakistan right now?
Not for routine public use, as far as the sources we could check show. The newest source we found that is about Pakistan is a guest editorial in the Annals of King Edward Medical University, published on 30 September 2025. It says the Drug Regulatory Authority of Pakistan (DRAP) has approved Dengvaxia, but not for routine mass immunisation. It also says Qdenga has not been approved for use in Pakistan.
We found no DRAP announcement of a routine dengue vaccine since then. That is a gap in what could be found, not proof that nothing has changed. Treat the status as dated, and check it yourself on the day you plan to book.
What are the side effects, and who should be careful?
For Qdenga, the EU label lists the most common side effects as pain and redness where the injection went in, headache, muscle pain, feeling generally unwell, and weakness. They may affect more than 1 in 5 people. The label says these are usually mild to moderate and clear within a few days. Fever is less common, with up to 1 in 10 people getting it.
Dengvaxia carries a different warning, and it matters for anyone offered it. The editorial says it is approved for people aged 9 to 45 with prior dengue exposure. It also says that giving it to people who were never infected has been linked to a higher risk of severe dengue if they are infected later. Testing before vaccination is hard in settings with few resources, such as Pakistan.
The maker has decided to discontinue Dengvaxia because of low global demand. Singapore’s Ministry of Health says the decision was not made for safety reasons, and that people who finished the recommended doses need no extra follow up. The editorial calls Qdenga suitable for a wider group, including people who were never infected. The EU label summary we checked does not say that, so ask the clinic to show you the leaflet. The EU summary also says Qdenga must not be used in women who are pregnant or breastfeeding. Check the full product information, and ask a doctor before you decide.
You have a fever right now, you have had dengue before, or you are pregnant or breastfeeding. Get a doctor’s advice before any vaccine decision. Dengue warning signs need care the same day, and they often start after the fever has gone away. Go to the nearest emergency room, or call your local emergency number (1122 in parts of Pakistan), if you have severe belly pain, repeated vomiting, rapid breathing, bleeding from the gums or nose, blood in vomit or stool, restlessness, pale cold skin, being very thirsty, or you feel very weak.
Does a dengue vaccine treat dengue or replace mosquito control?
No on both counts. A vaccine is for prevention in people who qualify. The WHO says there is no specific treatment for dengue, so once an infection has started, care is supportive: rest, plenty of fluids, paracetamol for pain, and no ibuprofen or aspirin, because they can increase the risk of bleeding.
The WHO says dengue prevention relies on vector control. That means removing artificial containers that hold water, covering water containers, emptying and cleaning domestic water storage containers every week, and using personal protection such as clothing that covers the body, mosquito nets, window screens, and repellents containing DEET, picaridin or IR3535. Our guide to mosquito season repellent, coils and netting covers those choices in detail, and dengue symptoms, warning signs and prevention covers the warning signs.
A vaccine protects the people it is licensed for. It does not touch a fever that has already started. You will find more in our Barsaat and Flood Season hub.
What should you ask a clinic before booking a dengue vaccine?
- Ask for the exact product name. Qdenga and Dengvaxia are different products with different rules, so a general answer is not enough.
- Ask whether it is registered in Pakistan. Then check the DRAP website yourself, because a clinic’s word is not the same as a registration.
- Ask who it is for. Check the age range, and ask whether a past dengue infection matters for that product.
- Ask whether it is part of routine immunisation or offered as a private option. The 2025 editorial says Dengvaxia was not approved for routine mass immunisation.
- Ask how many doses are needed and when the next one is due. The EU label for Qdenga describes two injections three months apart.
- Ask about side effects and what to do if a fever starts after a dose. Write the answers down.
- Ask for the price in writing. This article quotes no prices, because prices change and we did not verify a current one.
The written answer rule
Before you pay a deposit, ask the clinic to write the product name, its registration status and the eligibility rules on one sheet. If the answer comes back vague, book the mosquito steps now and check again on a later date.
If you are also planning other shots, our guides on flu vaccines in Pakistan, the typhoid vaccine and hepatitis B and C testing and vaccines cover those separately.
What about dengue vaccines in India?
This article did not confirm an Indian approval of any dengue vaccine against an official CDSCO listing, so treat news reports on the subject as unconfirmed. Treat India as a separate question. An Indian decision does not register a product in Pakistan, and it does not tell you what a clinic in Pakistan can offer.
Bottom line: no routine dengue vaccine is confirmed for Pakistan in the sources checked here, the approved product is being discontinued, and the mosquito and warning sign steps stay the same whichever vaccine you hear about.
Dengue vaccine questions people ask
Is there a dengue vaccine in Pakistan?
Not for routine public use, as far as the sources we could check show. A September 2025 editorial says DRAP approved Dengvaxia but not for routine mass immunisation, and that Qdenga has not been approved. Check the current status with DRAP and your clinic before you plan.
What is the dengue vaccine price in Pakistan?
This article quotes no price. We did not verify a current figure, and prices change. Ask the clinic or pharmacy for the price in writing, and ask about registration status first.
Is dengue vaccine available in India?
This article did not confirm an Indian approval of any dengue vaccine against an official CDSCO listing. Check with CDSCO or a clinic before you rely on any news report.
What is Qdenga?
Qdenga is a dengue vaccine developed by Takeda, described in the 2025 Pakistan editorial as a tetravalent live attenuated vaccine. It is given as two injections three months apart, and the EU label covers people from age 4.
Is dengue vaccine safe?
The EU label lists mild to moderate common side effects for Qdenga, such as pain at the injection site, headache and muscle pain. The EU summary says Qdenga must not be used in women who are pregnant or breastfeeding. Dengvaxia has a specific warning: giving it to people who were never infected has been linked to a higher risk of severe dengue later. Ask about your own history first.
Is dengue vaccine effective?
The EU summary says Qdenga protects against fever and hospitalisation from dengue disease caused by any of the four dengue virus types. Its main trial enrolled about 20,000 children and adolescents aged 4 to 16 and followed fever outcomes for 12 months after the second injection and hospitalisation for 18 months, so the figures do not map directly onto every adult.
What side effects should you expect after a dengue vaccine?
The most common side effects, which may affect more than 1 in 5 people, are pain or redness where the injection went in, headache, muscle pain, a general feeling of being unwell, or weakness. The EU summary says these are usually mild to moderate and clear within a few days. Fever is less common, reported in up to 1 in 10 people.
How many doses of dengue vaccine are needed?
For Qdenga, the EU label describes two injections given three months apart. Confirm the schedule for the exact product your clinic offers, because schedules can differ between products.
Who is eligible for a dengue vaccine?
It depends on the product. The Qdenga EU label starts at age 4, WHO recommends Qdenga for ages 6 to 16 in high transmission settings, and the Dengvaxia approval covers ages 9 to 45 with prior dengue exposure.
Does a dengue vaccine treat dengue?
No. A dengue vaccine is for prevention in people who qualify. The WHO says there is no specific treatment for dengue, so care after an infection starts is supportive, with rest, fluids and checks for warning signs.
Do you still need mosquito control after a dengue vaccine?
Yes. The WHO says dengue prevention relies on vector control, so removing containers that hold water, covering stored water, and using nets and repellent still matter whichever vaccine you have.
Sources
- Annals of King Edward Medical University: “Combatting Dengue Epidemics: Bridging Gaps with Vaccine Innovation” (editorial, 30 September 2025)
- World Health Organization: Dengue and severe dengue (fact sheet)
- European Medicines Agency: Qdenga, EPAR summary
- Singapore Ministry of Health: notice on discontinuation of Dengvaxia and ongoing monitoring of dengue vaccines (9 September 2026)